Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2′-deoxy-2′-α-fluoro- 2′-β-C-methylguanosine

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2566-2575

  Lam, Angela M ^a   Espiritu, Christine ^a   Murakami, Eisuke ^a   Zennou, Veronique ^a   Bansal, Shalini ^a   Micolochick Steuer, Holly M ^a   Niu, Congrong ^a   Keilman, Meg ^a   Bao, Haiying ^a   Bourne, Nigel ^b   Veselenak, Ronald L ^b   Reddy, P Ganapati ^a   Chang, Wonsuk ^a   Du, Jinfa ^a   Nagarathnam, Dhanapalan ^a   Sofia, Michael J ^a   Otto, Michael J ^a   Furman, Phillip A ^a  

^a PHARMASSET INC   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; DNA POLYMERASE; PSI 352938; PSI 354091; PSI 354519; RIBAVIRIN; RNA POLYMERASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN LUNET; CONTROLLED STUDY; CROSS RESISTANCE; DRUG INHIBITION; DRUG POTENTIATION; EMBRYO; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPLICON; RNA SYNTHESIS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYCLIC P-OXIDES; DEOXYGUANOSINE; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HUMANS; NUCLEOSIDES; PRODRUGS; REPLICON; RNA, VIRAL;

EID: 79956313517     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00032-11     Document Type: Article

References (55)

1. Ali, S., et al. 2008. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother. 52:4356-4369.
2. Alter, H. J. 2005. HCV natural history: the retrospective and prospective in perspective. J. Hepatol. 43:550-552. (Pubitemid 41253216)
3. Birschmann, I., and U. Walter. 2004. Physiology and pathophysiology of vascular signaling controlled by guanosine 3′,5′-cyclic monophosphate-dependent protein kinase. Acta Biochim. Pol. 51:397-404.
4. Blight, K. J., J. A. McKeating, J. Marcotrigiano, and C. M. Rice. 2003. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 77:3181-3190.
5. Bressanelli, S., L. Tomei, F. A. Rey, and R. De Francesco. 2002. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 76:3482-3492. (Pubitemid 34224549)
6. Carroll, S. S., and D. B. Olsen. 2006. Nucleoside analog inhibitors of hepatitis C virus replication. Infect. Disord. Drug Targets 6:17-29.
7. Charneau, P., M. Alizon, and F. Clavel. 1992. A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J. Virol. 66:2814-2820.
8. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
9. De Clercq, E. 2004. Antiviral drugs in current clinical use. J. Clin. Virol. 30:115-133.
10. Di Bisceglie, A. M., and J. H. Hoofnagle. 2002. Optimal therapy of hepatitis C. Hepatology 36:S121-S127.
11. Foster, G., and P. Mathurin. 2008. Hepatitis C virus therapy to date. Antivir. Ther. 13(Suppl. 1):3-8.
12. Fridell, R. A., D. Qiu, C. Wang, L. Valera, and M. Gao. 2010. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54:3641-3650.
13. Fried, M. W., et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
14. Furman, P. A., A. M. Lam, and E. Murakami. 2009. Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends. Future Med. Chem. 1:1429-1452.
15. Gane, E., et al. 2009. Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: safety, pharmacokinetics, and virologic results from INFORM-1, abstr. 193. Abstr. 60th Annu. Meet. Am. Assoc. Study Liver Dis.
16. Gane, E. J., et al. 2010. Sustained virologic response following RG7128 1500 mg BID PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders, abstr. 37. Abstr. 45th Annu. Meet. Eur. Assoc. Study Liver.
17. Gunic, E., et al. 2007. Cyclic monophosphate prodrugs of base-modified 2′-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication. Bioorg. Med. Chem. Lett. 17:2452-2455.
18. Hadziyannis, S. J., et al. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-355.
19. Hassan, A. E., et al. 2003. Synthesis and antiviral evaluation of 2′,3′-dideoxy-2′-fluoro-3′-C-hydroxymethyl-beta-D- arabinofuranosyl pyrimidine nucleosides. Nucleosides Nucleotides Nucleic Acids 22:891-894. (Pubitemid 37139283)
20. Howe, A. Y., et al. 2008. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob. Agents Chemother. 52:3327-3338.
21. Jensen, D. M., et al. 2010. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PEG-IFN alfa-2a (40KD)/RBV: planned week 12 interim analysis from the Propel study, abstr. 81. Abstr. 61st Annu. Meet. Am. Assoc. Study Liver Dis.
22. Kim, A. Y., and J. Timm. 2008. Resistance mechanisms in HCV: from evolution to intervention. Expert Rev. Anti Infect. Ther. 6:463-478.
23. Kolykhalov, A., et al. 2009. In vitro characterization of INX-189, a highly potent phosphoramidate nucleoside analogue inhibitor of HCV, abstr. 101. Abstr. HEPDART: Frontiers in Drug Development for Viral Hepatitis.
24. Kondo, Y., et al. 2010. Lymphotropic HCV strain can infect human primary naive CD4(+) cells and affect their proliferation and IFN-gamma secretion activity. J. Gastroenterol. 46:232-241.
25. Koutsoudakis, G., E. Herrmann, S. Kallis, R. Bartenschlager, and T. Pietschmann. 2007. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J. Virol. 81:588-598. (Pubitemid 46067886)
26. Kuntzen, T., et al. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-1778.
27. Lalezari, J., et al. 2008. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500mg BID for 28 days, abstr. 66. Abstr. 43rd Annu. Meet. Eur. Assoc. Study Liver.
28. Lalezari, J., et al. 2011. Once daily PSI-7977 plus PegIFN/RBV in a phase 2B trail: rapid virologic suppression in treatment-naive patients with HCV GT2/GT3, abstr. 61. Abstr. 46th Annu. Meet. Eur. Assoc. Study Liver.
29. Lam, A. M., and D. N. Frick. 2006. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J. Virol. 80:404-411.
30. Lam, A. M., et al. 2010. PSI-7851, a pronucleotide of beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob. Agents Chemother. 54:3187-3196.
31. Lawitz, E., et al. 2010. High rapid virologic response (RVR) with PSI-7977 daily dosing plus PEG-IFN/RBV in a 28-day phase 2a trial, abstr. 806. Abstr. 61st Am. Assoc. Study Liver Dis.
32. Lawitz, E., et al. 2009. Potent antiviral activity observed with PSI-7851, a novel nucleotide polymerase inhibitor for HCV, following multiple ascending oral doses for 3 days in patients with chronic HCV infection, abstr. 102. Abstr. HepDart.
33. Le Pogam, S., et al. 2006. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351:349-359.
34. Le Pogam, S., et al. 2006. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J. Virol. 80:6146-6154. (Pubitemid 43849192)
35. Le Pogam, S., et al. 2008. Low level of resistance and low viral fitness in vitro and absence of resistance mutations in baseline quasispecies may contribute to high barrier to R1626 resistance in vivo, abstr. 6. Abstr. 3rd Int. Workshop Hepatitis C-Resist. New Compounds.
36. Le Pogam, S., et al. 2008. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61:1205-1216.
37. Le Pogam, S., et al. 2009. No evidence of R7128 drug resistance after up to 4 weeks treatment of GT1,2 and 3 hepatitis c virus infected individuals. J. Hepatol. 50S:348.
38. Lohmann, V., S. Hoffmann, U. Herian, F. Penin, and R. Bartenschlager. 2003. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77:3007-3019. (Pubitemid 36228086)
39. Lucas, K. A., et al. 2000. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52:375-414.
40. McCarville, J. F., et al. 2010. In vitro and in vivo resistance profile of IDX184, a novel nucleotide analog for the treatment of HCV infection, abstr. 9. Abstr. 5th Int. Workshop Hepatitis C-Resist. New Compounds.
41. McCown, M. F., et al. 2008. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 52:1604-1612.
42. Meppen, M., et al. 2009. Cyclic phosphoramidates as prodrugs of 2′-C-methylcytidine. Eur. J. Med. Chem. 44:3765-3770.
43. Migliaccio, G., et al. 2003. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278:49164-49170.
44. Murakami, E., et al. 2007. Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob. Agents Chemother. 51:503-509.
45. Murakami, E., et al. 2010. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J. Biol. Chem. 285:34337-34347.
46. Nguyen, T. T., et al. 2003. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob. Agents Chemother. 47:3525-3530.
47. Reddy, P. G., et al. 2010. 2′-Deoxy-2′-alpha-fluoro-2′- beta-C-methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938. Bioorg. Med. Chem. Lett. 20:7376-7380.
48. Sofia, M. J., et al. 2010. Discovery of a beta-D-2′-deoxy-2′- alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53:7202-7218.
49. Sommadossi, J. P., R. F. Schinazi, C. K. Chu, and M. Y. Xie. 1992. Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells. Biochem. Pharmacol. 44:1921-1925.
50. Stuyver, L. J., et al. 2002. Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues. Antimicrob. Agents Chemother. 46:3854-3860.
51. Stuyver, L. J., et al. 2006. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir. Chem. Chemother. 17:79-87.
52. Stuyver, L. J., et al. 2003. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J. Virol. 77:10689-10694. (Pubitemid 37129715)
53. Tomei, L., et al. 2003. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77:13225-13231. (Pubitemid 37494318)
54. Vaandrager, A. B., and H. R. de Jonge. 1996. Signalling by cGMP-dependent protein kinases. Mol. Cell. Biochem. 157:23-30.
55. Yi, M., R. A. Villanueva, D. L. Thomas, T. Wakita, and S. M. Lemon. 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl. Acad. Sci. U. S. A. 103:2310-2315.